1.
Haggarty SJ. The principle of complementarity: chemical versus biological space. Curr Opin Chem Biol. 2005;9(3):296-303. doi:10.1016/j.cbpa.2005.04.006.
1.
Hung DT, Rubin EJ. Chemical biology and bacteria: not simply a matter of life or death. Curr Opin Chem Biol. 2006;10(4):321-6. doi:10.1016/j.cbpa.2006.06.016.
1.
Wagner BK, Haggarty SJ, Clemons PA. Chemical genomics: probing protein function using small molecules. Am J Pharmacogenomics. 2004;4(5):313-20. http://content.wkhealth.com/linkback/openurl?issn=1175-2203&volume=4&issue=5&spage=313.
1.
Wagner BK. The resurgence of phenotypic screening in drug discovery and development. Expert Opin Drug Discov. 2016;11(2):121-5. doi:10.1517/17460441.2016.1122589.
1.
Lander ES. Eric S. Lander. Nat Rev Drug Discov. 2004;3(9):730. doi:10.1038/nrd1514.
1.
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231.
1.
Clemons PA. Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol. 2004;8(3):334-8. doi:10.1016/j.cbpa.2004.04.002.
1.
Buskirk AR, Landrigan A, Liu DR. Engineering a ligand-dependent RNA transcriptional activator. Chem Biol. 2004;11(8):1157-63. doi:10.1016/j.chembiol.2004.05.017.
1.
Theriault JR, Felts AS, Bates BS, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012;22(1):76-81. doi:10.1016/j.bmcl.2011.11.077.
1.
Geng B, Basarab G, Comita-Prevoir J, et al. Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): pyridodiazepine amines. Bioorg Med Chem Lett. 2009;19(3):930-6. doi:10.1016/j.bmcl.2008.11.113.